SCHEMBL3985960

SCHEMBL3985960

COc1cc(NC(=O)OCc2cccc(Nc3c4ccccc4nc4ccccc34)c2)cc(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 5/20 0.59
TOP2B Q02880 5/20 0.59
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 4/20 0.48
KMT2A Q03164 3/20 0.48
RAD52 P43351 2/20 0.48
GFER P55789 2/20 0.48
MEN1 O00255 2/20 0.48
KDM1A O60341 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
PDE4B Q07343 1/20 0.47
GLA P06280 1/20 0.46
TACR3 P29371 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7234860 0.94 TOP2A (0.56) TOP2ATOP2BTP53MAPTL3MBTL1
SCHEMBL7567719 0.88 TOP2A (0.73) TOP2ATOP2BTP53MAPTL3MBTL1
SCHEMBL3980328 0.88 POLB (0.60) TOP2ATOP2BMAPTL3MBTL1POLB
SCHEMBL7564523 0.85 TOP2A (0.71) TOP2ATOP2BTP53MAPTPOLB
SCHEMBL9593593 0.84 TOP2A (0.64) TOP2ATOP2BTP53MAPTL3MBTL1
SCHEMBL9594614 0.84 TOP2A (0.64) TOP2ATOP2BTP53MAPTL3MBTL1
SCHEMBL9593964 0.84 TOP2A (0.76) TOP2ATOP2BMAPTL3MBTL1POLB
SCHEMBL9592763 0.82 TOP2A (0.56) TOP2ATOP2BTP53MAPTL3MBTL1
SCHEMBL9595534 0.82 TOP2A (0.56) TOP2ATOP2BTP53MAPTL3MBTL1
SCHEMBL9594240 0.81 TOP2A (0.60) TOP2ATOP2BTP53MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1380574-B1 9-aminoacridine derivates and process for the preparation thereof SAMJIN PHARM CO LTD (KR) 2009-05-20 EP disclosed
EP-1380574-A1 9-aminoacridine derivates and process for the preparation thereof Samjin Pharmaceutical Co., Ltd. (KR) 2004-01-14 EP disclosed
US-6620936-B2 Antitumor agents, topoisomerase inhibitors, notoxic SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-16 US disclosed
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2002-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof ALKBH1, ADCY9, CCR9 TOP2A 1105/4885TOP2B 841/4885TP53 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.